Director Isaac Cheng resigns from Amylyx board effective Nov 1, 2022

Amylyx Pharmaceuticals, Inc.

Isaac Cheng, MD, resigned from the board of directors on November 1, 2022.
Resignation is not due to any disagreement with the company on operations, policies, or accounting.
Board size reduced by one; no replacement named in the filing.
Company thanked Dr. Cheng for his service and contributions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Isaac Cheng

Member of the Board of Directors

AMLX · Amylyx Pharmaceuticals, Inc.

Effective: 2022-11-01
Filed: November 2, 2022, 7:59 PM ET

On November 1, 2022, Isaac Cheng, MD, a member of the board of directors of Amylyx Pharmaceuticals, Inc. (the “Company”), submitted his resignation from the board of directors, effective as of close of business on November 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Isaac Cheng resigned as Member of the Board of Directors at Amylyx Pharmaceuticals, Inc..

Action: resigned
Role: Member of the Board of Directors

Exact text from the filing

On November 1, 2022, Isaac Cheng, MD, a member of the board of directors of Amylyx Pharmaceuticals, Inc. (the “Company”), submitted his resignation from the board of directors, effective as of close of business on November 1, 2022.

View on SEC.gov

Amylyx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-275812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.